EVEREST MED(01952),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01952 EVEREST MED

Not Yet Opened 12-11 16:08:03

43.760

+0.160

+0.37%

High44.700	Low43.140	Vol1.97M
Open43.600	D1 Closing43.600	Amplitude3.58%
Mkt Cap15.49B	Tradable Cap15.49B	Total Shares354.00M
T/O86.35M	T/O Rate0.56%	Tradable Shares354.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"EVEREST MED","latestPrice":43.76,"timestamp":1765440483004,"preClose":43.6,"halted":0,"volume":1973000,"delay":0,"floatShares":354000000,"shares":354000000,"eps":-3.5809496641764325,"marketStatus":"Not Yet Opened","change":0.16,"latestTime":"12-11 16:08:03","open":43.6,"high":44.7,"low":43.14,"amount":86353349,"amplitude":0.03578,"askPrice":43.8,"askSize":500,"bidPrice":43.76,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-2.248947461751568,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765503000000},"marketStatusCode":0,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":43.6,"openAndCloseTimeList":[[1765416600000,1765425600000],[1765429200000,1765440000000]],"volumeRatio":0.8826273001308099,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"1175584652","title":"EVEREST MED (01952) Enters Commercialization Service Agreement and Licensing Pact with Hissen Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=1175584652","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175584652?lang=en_us&edition=fundamental","pubTime":"2025-12-11 17:06","pubTimestamp":1765444001,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) announced that on December 11, 2025, Everest Medicines (a wholly-owned subsidiary of the company) entered into a commercialization service agreement with Hissen Bio. Under this...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01952","BK1574","BK1161"],"gpt_icon":0},{"id":"2590596529","title":"Everest Medicines Files Director List with HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2590596529","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590596529?lang=en_us&edition=fundamental","pubTime":"2025-12-11 16:55","pubTimestamp":1765443347,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. has released an updated list of its board of directors and their respective roles and committee memberships, filed to the Hong Kong Stock Exchange. The executive directors are Mr. Yifang Wu , Mr. Yongqing Luo , and Mr. Ian Ying Woo . Non-executive directors include Mr. Wei Fu , Mr. William Ki Chul Cho, and Mr. Xin Sun. The independent non-executive directors are Ms. Hoi Yam Chui, Mr. Yifan Li, and Mr. Shidong Jiang. In terms of committee appointments, Mr. Yifan Li serves as Chairperson of the Audit Committee, with Ms. Hoi Yam Chui and Mr. Shidong Jiang as members. Ms. Hoi Yam Chui is the Chairperson of the Remuneration Committee, joined by Mr. Yifang Wu and Mr. Shidong Jiang. Mr. Yifang Wu leads the Nomination Committee as Chairperson, with Ms. Hoi Yam Chui and Mr. Yifan Li as members.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL6p05PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","01952","BK1574"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09860","02431","00460","BK1504","02551","LU0072462343.USD","06963","LU1808992512.USD","HK0000306701.USD","BK1216","09639","01911","LU1917777945.USD","02525","LU1008478684.HKD","02420","BK1582","BK1502","LU0214875030.USD","LU2177674079.SGD","BK1516","IE00B0JY6N72.USD","02567","BK1114","01952","02121","02595","02696","BK1591","LU1794554557.SGD","02627","BK1222","BK1225","IE0003851619.USD","LU0082770016.USD","01600","BK1136","LNNGY","LU0326950275.SGD","LU0823414478.USD","LU0164865239.USD","LU0541501648.USD","LU0348784397.USD","BK1167","80992","01739","BK1128","01318","LU1969619763.USD","LU2125910500.SGD","LU0359201612.USD","00363","LU0149721374.USD","LU1366334578.USD","01519","02105","02511","LU2153591404.USD","SG9999015952.SGD","02509","03800","BK1608","02150","LU1048588211.SGD","BK1587","SGXZ90724238.SGD","BK1100","LU2097828805.USD","BK1158","LU1880383366.USD","IE00B8L5B284.USD","02650","LU0541502299.USD","HK0000252152.HKD","01877","02556","01405","LU1282649067.USD","BK1175","02167","LU0314109678.HKD","LU1497733631.SGD","LU1115378108.SGD","09956","LU2023250504.SGD","06657","BK1227","BK1583","LU0228659784.USD","09959","LU0819121731.USD","BK1139","LU0823426480.USD","LU1770036033.HKD","BK1523","LU0049112450.USD","LU0251144936.SGD","SG9999006514.SGD","02488","BK1526","BK1528","LU0084288322.USD","LU0164880469.USD","LU0431992006.USD","LU0456827905.SGD","LU2399975544.HKD","BK1179","01907","IE00BD6J9T35.USD","BK1557","BK1598","BK1131","06086","01070","00017","LU0871576103.HKD","LU1508157978.USD","BK1500","BK1616","02018","LU2328871848.SGD","LU0737861772.HKD","LU1868837565.USD","SG9999015986.USD","BK1609","LU0620787316.HKD","00798","00960","LU0708995583.HKD","BK1589","BK1539","BK1147","BK1592","06168","01880","06613","LU0211977185.USD","BK1594","06913","BYDDY","IE00B8HQ1Z84.USD","06862","BK1168","LU1961090484.USD","02276","BK1233","01458","02411","LU0329678170.USD","LU0348783233.USD","03939","LU1226287529.USD","LU1868837722.USD","BK1169","LU0261950470.USD","BK1148","02670","BK1593","BK1125","LU0455707207.USD","03738","BK1559","SG9999015978.USD","SG9999001226.SGD","BK1141","BK1127","BK1190","IE00B5MMRT66.SGD","SG9999011746.SGD","BK1606","BK1224","01117","HK0000252160.HKD","SG9999001051.SGD","LU0588546209.SGD","02587","06919","LU0345776255.USD","LU0417516571.SGD","BK1230","03650","LU0052756011.USD","LU0052750758.USD","IE00BQXX3C00.GBP","BK1184","LU1039395188.USD","BK1189","BK1258","LU1226287875.USD","LU0244354667.USD","LU0269904917.USD","LU1868838027.USD","LU2348774022.SGD","02453","LU2294711713.HKD","BK1117","LU2778985437.USD","IE00BYV24P56.USD","LU0261947096.USD","SG9999001069.SGD","BK1556","03677","02013","LU1023057109.AUD","BK1207","LU0516422440.USD","LU2506952253.HKD","LU1211504680.USD","LU0499858602.USD","09699","06683","09955","01969","BK1521","02100","LU0588545904.SGD","02197","BK1150","06618","LU0880133367.SGD","SG9999006597.SGD","BK1240","BK1552","LU2039709279.SGD","02331","02228","BK1198","01809","SGXZ86797644.SGD","02279","LU2153592121.USD","02273","02315","BK1219","LU0502904849.HKD","02469","LU0762540952.USD","SG9999003461.SGD","LU2663582299.SGD","LU0231483743.USD","86618","LU0593848301.USD","LU0417516902.SGD","02145","02858","BK1183","02298","LU2008162690.USD","LU0043850808.USD","02552","LU0823038988.USD","LU0140636845.USD","BK1109","BK1518","LU1366334651.USD","IE00BGV7N243.SGD","LU1328615791.USD","LU2298064838.USD","BK1519","BK1585","LU0289739343.SGD","LU0348766576.USD","LU0650527681.SGD","LU0456846285.SGD","BK1155","LU0143863198.USD","SG9999015945.SGD","BK1524","06821","LU1282649810.SGD","LU2449936058.SGD","01640","LU0310800965.SGD","SG9999002562.SGD","BK1542","LU0359202008.SGD","BK1154","LU0048575426.USD","LU1235295612.USD","LU2460026573.USD","IE00BMCWC346.EUR","03709","IE00BZ08YT58.USD","LU1224709979.USD","00512","03681","01276","LU0823039010.USD","LU0640798160.USD","00699","LU0039217434.USD","BK1578","01735","IE00BZ08YR35.GBP","002594","BK1550","SG9999000418.SGD","06090","09911","09660","01211","06996","IE00BZ08YS42.EUR","LU2476274720.SGD","LU1719994722.HKD","02565","01378","LU0072913022.USD","BK1235","09636","LU0823414551.USD","LU0254981946.USD","LU1152091168.USD","BK1600","BK1116","BK1605","BK1221","LU0229945570.USD","02256","LU0289961442.SGD","BK1228","BK1604","BK1512","BK1515","IE00BQXX3F31.USD","LU1720050803.USD","00777","02096","LU0348827113.USD","LU0819123356.HKD","BK1554","LU0588545730.USD","LU2238339852.HKD","BK1607","HYDD.SI","01651","LU1267930227.SGD","LU0164872284.USD","00020","82020","LU0259732245.USD","02460","02400","BK1610","01530","IE0008368742.USD","09877","LU1880383440.USD","02142","LU0173614495.USD","LNVGY","LU0348767384.USD","LU0791591158.USD","09690","LU0572940350.SGD","LU0979878070.USD","00999","LU0348825331.USD","BK1124","00855","02533","LU0315179316.USD","LU0289960550.SGD","LU0175139822.USD","02590","LU0594300179.USD","LU0143863784.USD","LU0702159699.USD","SGXZ62798434.SGD","LU0505663152.USD","LU0605514214.HKD","09890","82331","LU1634259391.SGD","BK1178","LU0417516738.SGD","IE00BPRC5H50.USD","LU0327786744.USD","BK1160","IE0031814852.USD","LU0516422366.SGD","BK1191","LU1166156734.SGD","LU1102505929.USD","BK1257","BK1170","09927","06058","LU0320764599.SGD","BK1144","BK1164","LU0737861699.HKD","LU2348773727.SGD","BK1575","BK1237","LU0594300419.USD","LU1522347837.USD","LU0611395673.USD","LU1813983027.USD","BK1209","SG9999002950.SGD","03998","LU1861219969.SGD","03145","BK1229","BK1617","LU0865486749.SGD","02157","02889","02419","HK0000306685.HKD","BK1142","09992","BK1137","LU0831093199.SGD","09678","00451","BK1548","LU2249611893.SGD","LU0384037296.USD","BK1555","02382","06609","81211","SG9999000459.SGD","BK1193","LU0348805143.USD","02629","BK1197","BK1119","02598","09880","LU0370786039.SGD","ANPDY","LU1242518857.USD","00003","01833","LU0531970944.HKD","BK1522","LU0488056044.USD","BK1549","LU1303224171.USD","LU1807302812.USD","LU0287142896.SGD","LU0499858438.USD","LU0823397103.USD","BK1619","02268","02171","LU0856984785.SGD","LU0251143458.SGD","HK0000320264.USD","BK1186","BK1577","01585","09926","LU2097828474.EUR","02190","BK1579","06138","LU1981816686.USD","SG9999014674.SGD","LU0107464264.USD","00884","00875","LU0048580855.USD","BK1212","LU2424517915.HKD","BK1161","IE00B29SXG58.USD","LU0082770016.SGD","00384","LU1481107354.HKD","LU0572944931.SGD","LU2106854487.HKD","BK1509","LU1226287792.SGD","SG9999002463.SGD","LU0823397285.USD","HK0000165453.HKD","BK1111","SG9999001903.USD","01681","BK1553","LU0868486357.SGD","BK1163","LU1328277881.USD","IE00BGHQDM52.EUR","BK1530","BK1590","LU2506951792.HKD","LU2357125470.USD","00826","03396","BK1571","06608","01164","02158","LU0572939691.SGD","06060","BK1095","LU0588545490.SGD","LU2360107325.USD","SG9999002828.SGD","BK1239","LU0274383008.USD","BK1200","LU1251922891.USD","06988","09985","02886","02392","BK1595","LU0449515922.USD","LU2097828631.EUR","LU0463099449.HKD","03658","BK1574","BK1588","LU0511384066.AUD","BK1566","LU0634319403.HKD","LU0165289439.USD","IE0032431581.USD","LU0261950983.USD","BK1195","LU0449509016.USD","02177","LU1046422090.SGD","LU1634259557.SGD","02616","IE00BVYPNP33.GBP","06677","LU0791590937.USD","BK1126","01520","06855","IE0009570106.USD","LU2045819591.USD","SG9999001093.SGD","LU0509642566.USD","BK1618","03836","HK0000320223.HKD","LU0561508036.HKD","BK1520","00867","03896","BK1215","00305","02380","BK1214","80020","IE0003795394.USD","LU0067412154.USD","BK1171","01119","01773","LU0315178854.USD","LU1226288253.USD","LU0048597586.USD","IE00B543WZ88.USD","LU0516423174.USD","BK1188","LU0540923850.HKD","BK1134","BK1104","IE0008369823.USD","LU0516422952.EUR","02498","BK1110","LU0348735423.USD","00992","09923","LU2488822045.USD","BK1613","LU1831875114.USD","06160","LU1675838814.USD","LU1497733557.USD","00302","02057","LU0164939612.USD","00135","LU1861214812.USD","BK1596","LU1242518931.SGD","09878","01471","02020","LU0828237510.HKD","IE00BQXX3D17.EUR","01783","BK1247","LU1497734951.SGD","LU2242644610.SGD","LU3063872942.SGD","02506","02436","IE00BVYPNQ40.USD","BK1527","LU1951186391.HKD","09990","LU0531971595.HKD","BK1194","01093","LU0469268626.HKD","LU1770034418.SGD","00666","BK1151","LU1226288170.HKD","LU0345775950.USD","LU0128525689.USD","BK1560","LU0543330566.HKD","06633","00136","00656","BK1564","02155","LU2543165471.USD","BK1220","01762","BK1132","LU1939255532.USD","LU0329678337.USD","LU0823426308.USD","BK1096","00267","IE00B0169L03.USD","BK1253","BK1544","LU2476274308.USD","BK1586","01333","LU0307460666.USD","LU1960683339.HKD","LU0501845795.SGD","SG9999000475.SGD","02451","LU0823437842.USD","HK0000500386.USD","LU0054450605.USD","02250","IE00B031HY20.USD","LU0054237671.USD","LU1993786604.SGD","BK1531","LU0516423091.SGD","09919","LU0011963245.USD","LU0051755006.USD","01818","IE0034224299.USD","SG9999004220.SGD","00300","BK1540","LU2097828714.EUR","LU2097828557.USD","LU1152091754.HKD","LU1188198961.HKD","SG9999004311.SGD","LU1102505762.USD","00382","06100","LU1956131251.USD","BK1615","BK1597","06069","01440","BK1541","LU1974910355.USD","LU0828238088.HKD","LU0359201885.HKD","06186","IE00B031J352.USD","BK1140","01177","09961","09996","03680","01384","01939","00861","LU0264606111.USD","01448","BK1143"],"gpt_icon":1},{"id":"1166848418","title":"Everest Medicines (01952) Announces Monthly Equity Return for 30 November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1166848418","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166848418?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:05","pubTimestamp":1764759928,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited (01952) reported that as of 30 November 2025, the authorized share capital remained at 500,000,000 ordinary shares with a par value of USD 0.0001 each, totaling USD 50,000....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"1186169330","title":"HK Stock Movement | EVEREST MED (01952) Rises Over 5% as NEFECON® Showcases Latest Research Results at ASN Conference, Validating Market Value in IgA Nephropathy Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186169330","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186169330?lang=en_us&edition=fundamental","pubTime":"2025-11-14 11:12","pubTimestamp":1763089950,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) surged more than 5%, with shares up 4.07% to HK$48.56 at the time of writing, recording a turnover of HK$158 million. The company announced on its official WeChat account that...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2583258658","title":"Everest Medicines (SEHK:1952) Valuation Spotlight as New Ophthalmology Deal Expands Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2583258658","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583258658?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:32","pubTimestamp":1762968779,"startTime":"0","endTime":"0","summary":"Everest Medicines (SEHK:1952) has announced a new agreement with Visara Inc., gaining exclusive rights to develop and commercialize VIS-101 across Greater China and parts of Asia. This deal marks Everest's move into ophthalmology and broadens its late-stage product pipeline.\nSee our latest analysis for Everest Medicines.\nEverest Medicines’ latest move into ophthalmology comes as the company’s momentum shifts, with the recent 1-year total shareholder return reaching an impressive 32.84%. The...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-spotlight-as-new-ophtha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-spotlight-as-new-ophtha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1583","BK1574","MDCO","01952"],"gpt_icon":0},{"id":"2582490339","title":"Everest Medicines (SEHK:1952) Is Down 7.0% After Striking First Ophthalmology Deal With Visara Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2582490339","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582490339?lang=en_us&edition=fundamental","pubTime":"2025-11-11 11:19","pubTimestamp":1762831188,"startTime":"0","endTime":"0","summary":"On October 28, 2025, Everest Medicines Limited announced it had entered into an exclusive licensing agreement with Visara Inc. to develop, manufacture, and commercialize VIS-101, a novel bifunctional biologic for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, in Greater China, Singapore, South Korea, and select Southeast Asian countries, with upfront, milestone, and royalty payments totaling up to US$89 million plus additional expenses.\nThis...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-is-down-70-after-striking-first-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-is-down-70-after-striking-first-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1583","MDCO","01952","BK1574"],"gpt_icon":0},{"id":"1124671377","title":"Everest Medicines (01952) Announces Share Capital Movements for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1124671377","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124671377?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:21","pubTimestamp":1762428105,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited (stock code: 01952) has reported its monthly return on equity securities for the period ended 31 October 2025. The total authorised share capital remained at 500,000,000...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"2580285366","title":"What Everest Medicines (SEHK:1952)'s Exclusive VIS-101 Ophthalmology License Means for Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2580285366","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580285366?lang=en_us&edition=fundamental","pubTime":"2025-11-02 15:38","pubTimestamp":1762069129,"startTime":"0","endTime":"0","summary":"In late October 2025, Everest Medicines announced it had acquired an exclusive license to develop, manufacture, and commercialize VIS-101, a bifunctional biologic for wet AMD, diabetic macular edema, and retinal vein occlusion, in Greater China, Singapore, South Korea, and Southeast Asia through a collaboration with Visara, Inc.\nThis marks Everest Medicines' entry into ophthalmology, adding a late-stage asset expected to be Phase-3-ready in 2026 and enhancing its portfolio diversification...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/what-everest-medicines-sehk1952s-exclusive-vis-101-ophthalmo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/what-everest-medicines-sehk1952s-exclusive-vis-101-ophthalmo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","01952","BK4585","BK1583","MDCO","BK1161","VIS","BK1574"],"gpt_icon":0},{"id":"2580442202","title":"Everest Medicines (SEHK:1952): Valuation Insights Following Exclusive VIS-101 Ophthalmology Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2580442202","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580442202?lang=en_us&edition=fundamental","pubTime":"2025-11-01 09:44","pubTimestamp":1761961491,"startTime":"0","endTime":"0","summary":"Everest Medicines (SEHK:1952) has secured exclusive rights to develop and commercialize VIS-101, a promising bifunctional treatment for eye conditions like wet AMD, across Greater China and parts of Asia. This strategic move underscores the company’s ambitions in ophthalmology and signals potential growth ahead.\nSee our latest analysis for Everest Medicines.\nEverest Medicines’ exclusive VIS-101 deal adds momentum to a year already marked by strong long-term performance. The company posted an...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-insights-following-excl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-insights-following-excl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","01952","MDCO","BK4585","BK4588","VIS","BK1574","BK1583"],"gpt_icon":0},{"id":"1167592945","title":"EVEREST MED (01952) Secures Exclusive Rights to Ophthalmic Bispecific Drug VIS-101, Entering $40 Billion Blue Ocean Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1167592945","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167592945?lang=en_us&edition=fundamental","pubTime":"2025-10-30 10:42","pubTimestamp":1761792176,"startTime":"0","endTime":"0","summary":"On October 30, Hong Kong-listed biopharmaceutical company EVEREST MED (01952) announced an agreement with Visara to obtain exclusive rights for the clinical development, production, and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK4588","BK4585","01952","BK1574","VIS"],"gpt_icon":0},{"id":"2579152531","title":"BRIEF-Everest Medicines Announces Agreement With Visara","url":"https://stock-news.laohu8.com/highlight/detail?id=2579152531","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579152531?lang=en_us&edition=fundamental","pubTime":"2025-10-30 09:25","pubTimestamp":1761787509,"startTime":"0","endTime":"0","summary":"BRIEF-Everest Medicines Announces Agreement With VisaraOct 30  - Everest Medicines Ltd 1952.HK:AGREEMENT WITH VISARA TO DEVELOP AND COMMERCIALIZE VIS-101 IN GREATER CHINA AND OTHER ASIAN MARKETSTO PAY US$7 MILLION UPFRONTFurther company coverage: 1952.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nFWN3WA2K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01952","BK1161","BK1574"],"gpt_icon":0},{"id":"1127888378","title":"Everest Medicines (1952) and Visara Reach Exclusive License Deal for VIS-101","url":"https://stock-news.laohu8.com/highlight/detail?id=1127888378","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127888378?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:30","pubTimestamp":1761780635,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited (Stock Code: 1952) has signed an agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences (Nasdaq: NBP), on 28 October 2025 to develop, manufacture, and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"1117450614","title":"EVEREST MED (01952) Enters Agreement with VISARA for Development and Commercialization of VIS-101 in Greater China and Other Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1117450614","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117450614?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:12","pubTimestamp":1761779537,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) announced that on October 28, 2025, the company entered into an agreement with Visara, Inc. (VISARA), a subsidiary of NewBridge Pharmaceuticals (formerly known as I-Mab, listed on...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1574","BK1161","BK4588","VIS","01952","BK1583"],"gpt_icon":0},{"id":"2579814153","title":"Everest Medicines Secures Exclusive Rights to Develop and Commercialize VIS-101 in Greater China and Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2579814153","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579814153?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:03","pubTimestamp":1761778997,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited announced that it has entered into an agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences, to acquire exclusive rights to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain other Asian markets. VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, intended for the treatment of wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. The agreement allows Everest Medicines to expand into the ophthalmology therapeutic area. The transaction does not constitute a disclosable transaction under the Hong Kong Stock Exchange listing rules.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Lt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL54wRgR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","01952","BK1161"],"gpt_icon":0},{"id":"2579153894","title":"Everest Medicines - Agreement With Visara to Develop and Commercialize Vis-101 in Greater China and Other Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2579153894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579153894?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:02","pubTimestamp":1761778970,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nFWN3WA2K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","BK1583","01952"],"gpt_icon":0},{"id":"2579301641","title":"Novabridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for Vis-101 in Greater China and Certain Other Asian Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2579301641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579301641?lang=en_us&edition=fundamental","pubTime":"2025-10-30 06:27","pubTimestamp":1761776866,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nFWN3WA2EV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01952","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"1118217920","title":"HK Stock Connect Shareholding Changes | Oct 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1118217920","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118217920?lang=en_us&edition=fundamental","pubTime":"2025-10-28 08:38","pubTimestamp":1761611908,"startTime":"0","endTime":"0","summary":"According to disclosed data as of October 27, 2025, Qinhuangdao Port (03369), DL Holdings (01709), and Dazhong Utilities (01635) recorded the largest increases in HK Stock Connect shareholding...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00604","BK1589","01108","IE0034224299.USD","BK1247","LU1993786604.SGD","LU2039709279.SGD","02880","BK1574","01530","BK1506","BK1513","00777","BK1587","BK1171","BK1198","BK1124","LU0880133367.SGD","BK1522","SG9999006597.SGD","03369","02800","BK1558","LU0307460666.USD","01877","02050","BK1109","BK1161","BK1554","01385","BK1206","BK1511","01138","BK1175","LU0314109678.HKD","02208","BK1105","BK1207","00895","BK1166","BK1138","LU2488822045.USD","BK1576","00568","BK1516","02945","LU0320764599.SGD","00314","00187","HK0000500386.USD","LU0501845795.SGD","02367","LU2543165471.USD","BK1148","06821","LU0326950275.SGD","LU1152091754.HKD","BK1173","BK1208","01093","03069","BK1583","LU1226288170.HKD","BK1518","BK1154","BK1140","06127","LU0067412154.USD","00412","LU0052750758.USD","BK1141","LU1960683339.HKD","LU2328871848.SGD","BK1258","LU0708995583.HKD","02837","00588","06610","BK1116","BK1229","IE00B543WZ88.USD","LU1226287792.SGD","BK1515","BK1144","BK1191","SG9999004311.SGD","03738","LU1813983027.USD","00189","HK0000252160.HKD","01952","06693","BK1183","06680","LU1008478684.HKD","BK1593","02465","BK1137","09995","BK1205","BK1241","BK1552","LU0405327148.USD","01709","BK1531","BK1546","01347","LU1226287875.USD","BK1202","02600","BK1614","01065","01528","02186","BK1501","02865","LU1969619763.USD","BK1544","BK1537","IE00B5MMRT66.SGD","BK1568","01057","01330","BK1221","02828","LU1226288253.USD","BK1535","LU0315179316.USD","02402","01119","BK1582","02068","BK1104","01072","HK0000252152.HKD","BK1594","LU1152091168.USD","06869","MCHmain","LU1807302812.USD","IE0008368742.USD","IE0008369823.USD","SG9999014674.SGD","BK1149","BK1110","IE00BZ08YT58.USD","LU0588546209.SGD","02169","BK1606","LU0405327494.USD","IE00BZ08YS42.EUR","SG9999004220.SGD","LU1951186391.HKD","BK1521","BK1216","06616","BK1526","BK1519","09606","LU1328277881.USD","LU0072913022.USD","00358","01635","BK1592","BK1555","01053","BK1607","BK1505","BK1523","BK1610","03347","BK1240","02550","01341","BK1163","LU0140636845.USD","BK1225","09878","BK1129","IE00B031HY20.USD","02255","IE00BZ08YR35.GBP","BK1591","LU1226287529.USD","BK1236"],"gpt_icon":1},{"id":"1167981029","title":"EVEREST MED (01952) Holds Strategic Communication Meeting to Strengthen Global Layout and Achieve Leapfrog Development Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1167981029","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167981029?lang=en_us&edition=fundamental","pubTime":"2025-10-22 08:08","pubTimestamp":1761091709,"startTime":"0","endTime":"0","summary":"According to reports, the Hong Kong-based innovative pharmaceutical company EVEREST MED (01952) held a strategic investor communication meeting on October 21. Key members of the management team...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2577436385","title":"Everest Medicines (SEHK:1952) Valuation Spotlight as Leadership Transition Signals Strategic Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2577436385","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577436385?lang=en_us&edition=fundamental","pubTime":"2025-10-22 05:16","pubTimestamp":1761081388,"startTime":"0","endTime":"0","summary":"Everest Medicines (SEHK:1952) is set for a transition at the top, as Wei Fu steps down as chairman to focus on other commitments. Yifang Wu, a seasoned veteran from Fosun Pharma, will take the helm starting October 10, 2025.\nSee our latest analysis for Everest Medicines.\nInvestors seem to be weighing Everest Medicines’ leadership shake-up against its strong recent momentum, with the share price up 4% in the past day and 7% year-to-date. Despite short-term volatility, the company's one-year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-spotlight-as-leadership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-spotlight-as-leadership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDCO","BK1574","01952","BK1583","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.034},{"period":"1month","weight":-0.0258},{"period":"3month","weight":-0.2694},{"period":"6month","weight":-0.1326},{"period":"1year","weight":-0.094},{"period":"ytd","weight":-0.0959}],"compareEarnings":[{"period":"1week","weight":-0.0156},{"period":"1month","weight":-0.0437},{"period":"3month","weight":-0.0325},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.2667},{"period":"ytd","weight":0.2727}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.001711},{"month":2,"riseRate":0.4,"avgChangeRate":0.052947},{"month":3,"riseRate":0.4,"avgChangeRate":0.004093},{"month":4,"riseRate":0.2,"avgChangeRate":-0.095155},{"month":5,"riseRate":0.4,"avgChangeRate":-0.02945},{"month":6,"riseRate":0.8,"avgChangeRate":0.307082},{"month":7,"riseRate":0.2,"avgChangeRate":-0.114966},{"month":8,"riseRate":0.2,"avgChangeRate":-0.112869},{"month":9,"riseRate":0.6,"avgChangeRate":0.046163},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.155794}],"exchange":"SEHK","name":"EVEREST MED","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"EVEREST MED(01952),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest EVEREST MED(01952) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"EVEREST MED,01952,EVEREST MED股票,EVEREST MED股票老虎,EVEREST MED股票老虎国际,EVEREST MED行情,EVEREST MED股票行情,EVEREST MED股价,EVEREST MED股市,EVEREST MED股票价格,EVEREST MED股票交易,EVEREST MED股票购买,EVEREST MED股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"EVEREST MED(01952),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest EVEREST MED(01952) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}